Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
复制标题
DOI：
10.1002/ejhf.1920
复制
发表时间：
2020-11
影响因子：
18.2
通讯作者：
Lenihan D
中科院分区：
文献类型：
--
作者：
Lyon AR;Dent S;Stanway S;Earl H;Brezden-Masley C;Cohen-Solal A;Tocchetti CG;Moslehi JJ;Groarke JD;Bergler-Klein J;Khoo V;Tan LL;Anker MS;von Haehling S;Maack C;Pudil R;Barac A;Thavendiranathan P;Ky B;Neilan TG;Belenkov Y;Rosen SD;Iakobishvili Z;Sverdlov AL;Hajjar LA;Macedo AVS;Manisty C;Ciardiello F;Farmakis D;de Boer RA;Skouri H;Suter TM;Cardinale D;Witteles RM;Fradley MG;Herrmann J;Cornell RF;Wechelaker A;Mauro MJ;Milojkovic D;de Lavallade H;Ruschitzka F;Coats AJS;Seferovic PM;Chioncel O;Thum T;Bauersachs J;Andres MS;Wright DJ;López-Fernández T;Plummer C;Lenihan D
欧洲心脏病学会心力衰竭协会心脏肿瘤研究组与国际心脏肿瘤学会合作发表的立场声明，为肿瘤学家、血液肿瘤学家和心脏病专家提供了实用、易于使用且基于证据的风险分层工具，供肿瘤学家、血液肿瘤学家和心脏病学家在临床实践中使用，以便在接受已知会导致心力衰竭或其他严重心血管毒性的癌症治疗之前对肿瘤患者进行风险分层。在接受以下癌症治疗之前，为肿瘤患者提供基线风险分层形式：蒽环类化疗、HER2 靶向疗法（如曲妥珠单抗）、血管内皮生长因子抑制剂、针对 BCR-ABL 的慢性粒细胞白血病第二代和第三代多靶点激酶抑制剂、多发性骨髓瘤疗法（蛋白酶体抑制剂和 免疫调节药物）、RAF 和 MEK 抑制剂或雄激素剥夺疗法。应用这些风险分层形式将使临床医生能够在开始治疗之前将癌症患者的心血管并发症风险分为低、中、高和极高风险，目的是改进个性化方法，最大限度地降低癌症治疗引起的心血管毒性风险。
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
登录
查看更多内容
DOI：
10.1016/s0735-1097(00)00748-8
发表时间：
2000-08-01
影响因子：
24
作者：
Cardinale, D;Sandri, MT;Fiorentini, C
通讯作者：
Fiorentini, C
影响因子：
45.3
作者：
Cardinale, Daniela;Colombo, Alessandro;Cipolla, Carlo M.
通讯作者：
Cipolla, Carlo M.
影响因子：
45.3
作者：
Cornell, Robert F.;Ky, Bonnie;Lenihan, Daniel
通讯作者：
Lenihan, Daniel
影响因子：
158.5
作者：
Darby, Sarah C.;Ewertz, Marianne;Hall, Per
通讯作者：
Hall, Per
影响因子：
3.5
作者：
Adamo, Vincenzo;Ricciardi, Giuseppina Rosaria Rita;Russo, Antonio
通讯作者：
Russo, Antonio